All In Biotech

Drug Trial Radar · NCT06975878

Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group, 2-arm Study to Investigate the Safety and Immunogenicity of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers

Last checked: Nov 20, 2026Latest source record: Mar 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,092 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,092

Actual

Start

May 22, 2025

Primary completion

Aug 25, 2027

Study completion Aug 25, 2027

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
May 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 42 days, up to 112 days
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a Phase 3, randomized, modified double-blind study which aims to measure whether PCV21 vaccine (investigational pneumococcal conjugate vaccine) is safe and can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) compared with 15vPCV (Vaxneuvance, licensed pneumococcal conjugate vaccine) when they are administered with routine pediatric vaccines in infants aged from approximately 2 months (42 to 112 days). The study duration per participant will be up to approximately 20 months. The study vaccines (either PCV21 or 15-valent pneumococcal vaccines) will be administered at approximately 2, 4, and 11 to 15 months of age or at approximately 2, 3, 4, and 11 to 15 months of age (for preterm infants). Routine pediatric vaccines will be given at the same timepoints, as per local practice / recommendations. • There will be 5 (for full-term infants) or 6 (for preterm infants) study visits: * Full-term infants: Visit (V)01, V02 separated from V01 by 60 days, V03 separated from V02 by 30 days, V04 at 11 months of age until 15 months of age, V05 separated from V04 by 30 days. * Preterm infants: Visit (V)01, V02 separated from V01 by 30 days, V03 separated from V02 by 30 days, V04 separated from V03 by 30 days, V05 at 11 months of age until 15 months of age, V06 separated from V05 by 30 days.

Conditions

  • Pneumococcal Immunization
  • Healthy Volunteers

Interventions

  • PCV21 vaccineBiological

    Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

  • Vaxneuvance vaccineBiological

    Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

  • Hexyon vaccineBiological

    Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

  • M-M-RvaxPro vaccineBiological

    Pharmaceutical form:Powder and solvent for suspension for injection-Route of administration:Intramuscular or Subcutaneous

  • Varivax vaccineBiological

    Pharmaceutical form:Powder and solvent for suspension for injection-Route of administration:Intramuscular or Subcutaneous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Seroresponse rate for PCV21 and 15vPCV serotypesTime frame: 30 days post-toddler dose
  2. IgG concentration for PCV21 and 15vPCV serotypesTime frame: 30 days post-toddler dose

Locations

49 sites in 8 countries. Site status is shown where the registry gives one.

  • Investigational Site Number : 0560004

    Alken, Belgium

  • Investigational Site Number : 0560001

    Bruges, Belgium

  • Investigational Site Number : 0560002

    Edegem, Belgium

  • Investigational Site Number : 0560005

    Gozée, Belgium

  • Investigational Site Number : 0560007

    Leuven, Belgium

  • Investigational Site Number : 0560003

    Roeselare, Belgium

  • Investigational Site Number : 2030001

    Jindřichův Hradec, Czechia

  • Investigational Site Number : 2030009

    Krnov, Czechia

  • Investigational Site Number : 2030006

    Pilsen, Czechia

  • Investigational Site Number : 2030008

    Prague, Czechia

  • Investigational Site Number : 2330001

    Paide, Estonia

  • Investigational Site Number : 2330004

    Tallinn, Estonia

  • Investigational Site Number : 2330002

    Tartu, Estonia

  • Investigational Site Number : 2460008

    Espoo, Finland

  • Investigational Site Number : 2460001

    Helsinki, Finland

  • Investigational Site Number : 2460010

    Helsinki, Finland

  • Investigational Site Number : 2460005

    Jarvenpaa, Finland

  • Investigational Site Number : 2460003

    Kokkola, Finland

  • Investigational Site Number : 2460004

    Oulu, Finland

  • Investigational Site Number : 2460002

    Seinäjoki, Finland

  • Investigational Site Number : 2460007

    Tampere, Finland

  • Investigational Site Number : 2460009

    Turku, Finland

  • Investigational Site Number : 2760005

    Herxheim, Germany

  • Investigational Site Number : 2760006

    Hürth, Germany

  • Investigational Site Number : 2760014

    Hürth, Germany

  • Investigational Site Number : 2760013

    Krefeld, Germany

  • Investigational Site Number : 2760010

    Mönchengladbach, Germany

  • Investigational Site Number : 2760012

    Mönchengladbach, Germany

  • Investigational Site Number : 2760008

    Schönau am Königssee, Germany

  • Investigational Site Number : 2760003

    Wolfsburg, Germany

  • Investigational Site Number : 3000001

    Athens, Greece

  • Investigational Site Number : 3000002

    Athens, Greece

  • Investigational Site Number : 3000006

    Ioannina, Greece

  • Investigational Site Number : 3000005

    Thessaloniki, Greece

  • Investigational Site Number : 3800001

    Bari, Italy

  • Investigational Site Number : 3800008

    Foggia, Italy

  • Investigational Site Number : 3800010

    Lecce, Italy

  • Investigational Site Number : 3800007

    Milan, Italy

  • Investigational Site Number : 3800009

    Parma, Italy

  • Investigational Site Number : 3800004

    Rome, Lazio, Italy

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.